Gabapentin Capsule
Product Images NDC 63739-904

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 63739-904). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mckesson Corporation Dba Sky Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-100mg-cap1.jpg (Gabapentin 100mg Cap1)

Gabapentin Capsules USP 100 mg oral capsule packaging label showing one hundred (10 x 10) unit dose capsules. The label includes instructions to dispense the enclosed Medication Guide, storage conditions at 20° to 25°C (68° to 77°F), and details the product is distributed by McKesson Corporation dba Sky Packaging, packed by Ascend Laboratories, LLC, and manufactured by Akem Laboratories Ltd. in India.*

FDA Label Image

Gabapentin-300mg-cap1.jpg (Gabapentin 300mg Cap1)

Gabapentin Capsules USP 300 mg oral capsule packaging label from McKesson Corporation dba Sky Packaging. The label shows the NDC 63739-903-10 and includes dosage strength, quantity of 100 (10 x 10) unit dose capsules, barcode, storage instructions, and distributor, packager, and manufacturer details. It is Rx only and includes pharmacist dispensing instructions.*

FDA Label Image

Gabapentin-400mg-cap1.jpg (Gabapentin 400mg Cap1)

Packaging label for Gabapentin Capsules, USP 400 mg oral capsules. The label indicates a package quantity of 100 unit dose capsules (10 x 10). It includes instructions for the pharmacist to dispense the enclosed Medication Guide to each patient. Distributed by McKesson Corporation dba Sky Packaging, manufactured by Alkem Laboratories Ltd., India, and packaged by Ascend Laboratories, LLC.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A text panel showing the formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients. This formula supports dosing considerations but does not provide specific drug instructions.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph showing mean pain scores over an 8-week period comparing placebo with Gabapentin at 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing trend in pain scores over time compared to placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain scores over 7 weeks comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. Gabapentin groups show a decline in pain scores more than placebo over time.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar graph depicting the proportion of responders with at least 50% reduction in pain score at the endpoint of controlled PHN studies. The graph compares placebo (PBO) and Gabapentin (GBP) at doses of 3600 mg in Study 1, and 1800 mg and 2400 mg in Study 2, showing higher responder rates for Gabapentin groups versus placebo.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A chart comparing the difference in percentage on the vertical axis against daily dose in mg on the horizontal axis, showing data points for three studies labeled as Study a, Study b, and Study c. Study a is represented by black squares, Study b by gray squares, and Study c by white squares, with data points at various daily dose levels from approximately 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.